Immune Design Q3 Loss Widens - Quick Facts

(RTTNews) - Immune Design Corp. (IMDZ), a clinical-stage immunotherapy company, Wednesday said third-quarter net loss was $6.7 million or $0.55 per share compared to loss of $4.0 million or $10.81 per share for the third quarter 2013.

On average, three analysts polled by Thomson Reuters expected a loss of $0.36 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues improved to $3.54 million from last year's $129 thousand. Analysts expected revenues of $130 thousand.

The company expects to have cash to fund operations for approximately three years, without entering into any additional collaboration agreements or receiving any future milestone payments.